While also expecting results from RTOG 0924 and the PIVOTALboost trial [23, 27], the current literature suggest a benefit for ENI in cN0 prostate cancer patients with a very high risk of positive pelvic nodes, although primary staging was performed with PSMA-PET/CT. This evidence concerns the gene FOLH1 and prostate carcinoma.